Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 24, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Improving outcomes for retroperitoneal sarcomas: a work in progress.

Carol J Swallow1, Charles N Catton

  • 1Department of Surgery, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada. cswallow@mtsinai.on.ca

Surgical Oncology Clinics of North America
|February 28, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I-III Resectable Rectal Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial.

Annals of surgery·2026
Same author

Early recurrence and prognosis in patients undergoing resection of primary retroperitoneal sarcoma: an international, retrospective cohort study.

EClinicalMedicine·2026
Same author

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

International journal of radiation oncology, biology, physics·2026
Same author

Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG).

Cancer treatment reviews·2026
Same author

Accuracy of Histology and Malignancy Grade Between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study From the Prospective Retroperitoneal Sarcoma Registry (RESAR).

Annals of surgery·2025

This review summarizes prognostic factors and outcomes for retroperitoneal sarcoma, highlighting improved results due to multidisciplinary care. Expert assessment is crucial for managing this rare malignancy and minimizing treatment complications.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Sarcoma Research

Background:

  • Retroperitoneal sarcoma is a rare and complex malignancy.
  • Understanding prognostic factors is essential for patient management and treatment planning.

Purpose of the Study:

  • To review current understanding of prognostic factors and outcomes for retroperitoneal sarcoma.
  • To interpret factors contributing to improved patient outcomes.
  • To emphasize the role of multidisciplinary care.

Main Methods:

  • Literature review of studies published since 2000.
  • Inclusion of studies with patient cohorts of at least 30 individuals.
  • Interpretation of identified prognostic factors and outcome trends.

Related Experiment Videos

Last Updated: May 24, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Main Results:

  • Several factors have contributed to improved outcomes in retroperitoneal sarcoma.
  • Potential for good long-term patient survival is demonstrated.
  • Minimizing treatment-related morbidity is increasingly recognized as vital.

Conclusions:

  • Expert multidisciplinary assessment and care are paramount for managing retroperitoneal sarcoma.
  • A comprehensive approach improves outcomes and reduces treatment complications.
  • Continued research and collaboration are needed for this rare cancer.